Order Article Reprints

Katagiri S, Akahane D, Otsuki S, Suto A, Yamada A, Suguro T, Asano M, Yoshizawa S, Tanaka Y, Furuya N, et al. Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study. Vaccines. 2022; 10(9):1404. https://doi.org/10.3390/vaccines10091404

Katagiri, Seiichiro, Daigo Akahane, Shunsuke Otsuki, Arisa Suto, Akiko Yamada, Tamiko Suguro, Michiyo Asano, Seiichiro Yoshizawa, Yuko Tanaka, Nahoko Furuya, and et al. 2022. "Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study" Vaccines 10, no. 9: 1404. https://doi.org/10.3390/vaccines10091404

Katagiri, S., Akahane, D., Otsuki, S., Suto, A., Yamada, A., Suguro, T., Asano, M., Yoshizawa, S., Tanaka, Y., Furuya, N., Fujimoto, H., Okabe, S., Gotoh, M., Ito, Y., & Gotoh, A. (2022). Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study. Vaccines, 10(9), 1404. https://doi.org/10.3390/vaccines10091404